High-density tissue microarrays from prostate needle biopsies

por McCarthy, F, Dennis, N, Flohr, P, Jhavar, S, Parker, C, Cooper, C S
Publicado 2010

Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer

por Edwards, S, Campbell, C, Flohr, P, Shipley, J, Giddings, I, te-Poele, R, Dodson, A, Foster, C, Clark, J, Jhavar, S, Kovacs, G, Cooper, C S
Publicado 2005

An improved method for constructing tissue microarrays from prostate needle biopsy specimens

por McCarthy, F, Fletcher, A, Dennis, N, Cummings, C, O’Donnell, H, Clark, J, Flohr, P, Vergis, R, Jhavar, S, Parker, C, Cooper, C S
Publicado 2009

Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling

por Lee, Y-F, John, M, Edwards, S, Clark, J, Flohr, P, Maillard, K, Edema, M, Baker, L, Mangham, D C, Grimer, R, Wooster, R, Thomas, J M, Fisher, C, Judson, I, Cooper, C S
Publicado 2003

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

por Attard, G, Clark, J, Ambroisine, L, Mills, I G, Fisher, G, Flohr, P, Reid, A, Edwards, S, Kovacs, G, Berney, D, Foster, C, Massie, C E, Fletcher, A, De Bono, J S, Scardino, P, Cuzick, J, Cooper, C S
Publicado 2008

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

por Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G
Publicado 2015

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

por Reid, A H M, Attard, G, Ambroisine, L, Fisher, G, Kovacs, G, Brewer, D, Clark, J, Flohr, P, Edwards, S, Berney, D M, Foster, C S, Fletcher, A, Gerald, W L, Møller, H, Reuter, V E, Scardino, P T, Cuzick, J, de Bono, J S, Cooper, C S
Publicado 2010

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

por Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., de Bono, J.S.
Publicado 2020